DS
VIRX

David Shaw’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

David Shaw’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,883
Closed -$98K – 6029
2021
Q4 		$98K Sell
26,883
-9,379
-26% -$50K ﹤0.01% 5066
2021
Q3 		$291K Buy
+36,262
New +$357K ﹤0.01% 4366
2017
Q2 		– Sell
-854
Closed -$123K – 3580
2017
Q1 		$123K Buy
854
+163
+24% +$23.3K ﹤0.01% 3180
2016
Q4 		$87K Buy
691
+223
+48% +$31K ﹤0.01% 3355
2016
Q3 		$72K Sell
468
-631
-57% -$89.1K ﹤0.01% 3310
2016
Q2 		$126K Sell
1,099
-20
-2% -$2.22K ﹤0.01% 3232
2016
Q1 		$126K Sell
1,119
-7
-0.6% -$1.06K ﹤0.01% 3259
2015
Q4 		$212K Buy
1,126
+732
+186% +$137K ﹤0.01% 3536
2015
Q3 		$67K Sell
394
-2,107
-84% -$760K ﹤0.01% 3644
2015
Q2 		$1.58M Sell
2,501
-43
-2% -$22.9K ﹤0.01% 2382
2015
Q1 		$1.31M Sell
2,544
-1,098
-30% -$554K ﹤0.01% 2344
2014
Q4 		$1.95M Buy
3,642
+3,579
+5,681% +$1.61M ﹤0.01% 2305
2014
Q3 		$94K Sell
63
-1,005
-94% -$1.45M ﹤0.01% 3990
2014
Q2 		$1.46M Sell
1,068
-257
-19% -$298K ﹤0.01% 2584
2014
Q1 		$1.84M Sell
1,325
-1,341
-50% -$1.56M ﹤0.01% 2473
2013
Q4 		$2.65M Buy
2,666
+1,267
+91% +$1.31M ﹤0.01% 2248
2013
Q3 		$1.46M Buy
1,399
+1,096
+362% +$1.17M ﹤0.01% 2705
2013
Q2 		$332K Buy
+303
New +$338K ﹤0.01% 3512

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's VIRX Position: Q1 2022 in Review

David Shaw sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 26,883 shares — an estimated $98K sold.

David Shaw first reported a position in VIRX in Q2 2013 and held it in 18 quarters. The position peaked at $2.65M in Q4 2013. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • David Shaw reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 26,883 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $98K.
  • David Shaw first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • David Shaw's Viracta Therapeutics, Inc. Common Stock position peaked at $2.65M in Q4 2013.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.